Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-RTS-hIL-12 + Veledimex + Nivolumab in Recurrent Glioblastoma
NCT03636477Phase 1Completed
- Sponsor
- Alaunos Therapeutics
- Start
- Jun 2018
- Primary completion
- Oct 2020
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ad-rts-hil-12 in glioblastoma (GBM), sponsored by Alaunos Therapeutics. Primary endpoints: Number of Participants With Adverse Events and Number of Participants With Veledimex Dose Compliance. Started Jun 2018; status: completed.
02
Drugs
ad-rts-hil-12
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03636477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03636477.